“…PPV is low (3%–44%) while NPV is consistently high (91%–98%). Due to the high incidence of MPE, the NNG is low, especially in Canadians and Europeans ( Locharernkul et al., 2008 ; GlaxoSmithKline, 2009 ; US Food and Drug Administration, 2009 ; He et al., 2012 ; Shi et al., 2012 ; Amstutz et al., 2013 ; He et al., 2013 ; Lv et al., 2013 ; Caudle et al., 2014 ; Genin et al., 2014 ; ULC MP, 2015 ; Moon et al., 2016 ; Pfizer, 2016 ; Chen et al., 2017 ; Khor et al., 2017 ; Khosama et al., 2017 ; Deng et al., 2018 ; Fowler et al., 2019 ). But NNG is also low in North India ( An et al., 2010 ) due to a relatively high sensitivity (22.2%).…”